Login
$MXCT
$1.18 -$0.01 (0.84%) Live

$MXCT 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

Exhibit E – Form of Akron BioManufacturing Release Agreement

14 Oct 2026 8-K: Results of Operations and Financial Condition

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026

12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

At the 2026 annual meeting of stockholders of MaxCyte, Inc. (the “Company”) held on June 17, 2026 (the “Annual Meeting”), the Company’s stockholders considered and approved two proposals, each of which is described in more detail in the ...

16 Jun 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Na...

12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue

27 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) – MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gener...

24 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement

20 Mar 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On March 16, 2026, MaxCyte, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen...

12 Jan 2026 8-K: Results of Operations and Financial Condition

ROCKVILLE, MD, January 12, 2026 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generati...

12 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ROCKVILLE, MD, November 12, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell th...

05 Nov 2025 8-K: Results of Operations and Financial Condition

MaxCyte will now host its earnings conference call on November 12, 2025

22 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure

ROCKVILLE, MD, September 22, 2025 — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell t...

11 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 11, 2025, Ali Soleymannezhad’s employment as Chief Commercial Officer of MaxCyte, Inc. (the “Company”), ended. Mr. Soleymannezhad, in accordance with the terms of his Amended and Restated Severance Agreement dated July 1, 2024,...

06 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ROCKVILLE, MD, August 6, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell thera...

25 Jun 2025 8-K: Other Events

On June 25, 2025, MaxCyte, Inc. (the “Company”) announced that it had applied to the London Stock Exchange plc (the “LSE”) to cancel its admission of the Company’s common stock (the “Shares”) to trading on the AIM market (“AIM”) of the L...

18 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan.

07 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation ce...

11 Mar 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation...

30 Jan 2025 8-K: Regulation FD Disclosure

ROCKVILLE, MD – January 30, 2025 – MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support